Cardinal Health (CAH) reports revenue miss, significant profit reduction in Q3
Cardinal Health shares declined 6.0% to close at $190.51 on April 30, following its third-quarter fiscal 2026 earnings report which revealed a revenue miss and a significant net profit reduction. The large US healthcare services company ended the session down from its previous close of $202.77.
The decline stemmed from the company's Q3 fiscal 2026 results, reported on April 29, 2026. Cardinal Health posted revenue between $60.9 billion and $60.94 billion, an 11% year-on-year increase, but this fell short of the $62.1 billion consensus forecast. Net profit decreased to $399 million from $506 million in the prior year, primarily due to a $184 million goodwill impairment charge. This occurred despite an earnings per share beat of $3.17 against an expected $2.79 and a raised full-year 2026 EPS guidance to $10.70,$10.80. Shares initially gained 1.6% in premarket trading after the earnings release before reversing course.
Why a Goodwill Impairment Can Overshadow Stronger Earnings
Cardinal Health operates as a crucial intermediary in the vast United States healthcare system. The company primarily distributes pharmaceuticals and medical products to hospitals, pharmacies, and other healthcare providers. Essentially, they ensure that everything from prescription drugs to surgical gloves gets from manufacturers to the point of care efficiently, earning revenue through the volume of products they move and the services they provide to manage supply chains.
The primary driver behind Cardinal Health's share price decline was a significant goodwill impairment charge of $184 million, which dramatically reduced its net profit for the quarter. While the company reported an 11% year-on-year revenue increase, reaching between $60.9 billion and $60.94 billion, this figure still fell short of the $62.1 billion consensus forecast. This impairment charge, despite an earnings per share beat and raised full-year guidance, led to net profit decreasing to $399 million from $506 million in the prior year.
This substantial reduction in net profit, caused by the impairment, led to Cardinal Health shares closing down 6.0% at $190.51 on April 30, a notable drop from the previous close of $202.77.
Think of it like a builder who owns a plot of land valued at a certain price. If a new regulation or market shift makes that land less valuable for its intended purpose, the builder must officially acknowledge that loss in value, even if other projects are going well. This "write-down" directly impacts their reported profits, much like Cardinal Health's goodwill impairment affected its net profit, despite strong operational performance elsewhere.
Cardinal Health
Cardinal Health, Inc. (CAH) operates as an integrated healthcare services and products provider across the United States, Canada, Europe, and Asia. It delivers tailored solutions to a broad spectrum of healthcare entities, including hospitals, pharmacies, and ambulatory surgery centres. The company's operations are divided into two primary segments: Pharmaceutical and Medical. The Pharmaceutical segment focuses on distributing branded and generic pharmaceuticals, specialty products, and over-the-counter items, alongside offering services to manufacturers and providers, operating nuclear pharmacies, and managing medication therapy. The Medical segment manufactures, sources, and distributes a wide array of Cardinal Health branded medical, surgical, and laboratory products, encompassing gloves, needles, wound care, and surgical drapes, while also providing supply chain services. Incorporated in 1979, Cardinal Health is headquartered in Dublin, Ohio.